NCT07152821 2026-03-10
BATTMAN
Canadian Cancer Trials Group
Phase 3 Recruiting
Clinical Trials
21 trialsNCT05108298 2026-03-02
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Eastern Cooperative Oncology Group
Phase NA Recruiting
NCT05863195 2026-03-02
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04851119 2026-02-24
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
Phase 1/2 Recruiting
NCT06620302 2026-02-24
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
Children's Oncology Group
Phase 1/2 Recruiting
NCT06998940 2026-02-20
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06976710 2026-01-22
PC2
Surgical Outcomes Research Centre (SOuRCe)
Phase NA Recruiting
NCT06205485 2026-01-13
NEO-RT
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06880523 2025-12-18
SLIDE-HCC
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT06807437 2025-12-05
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
SWOG Cancer Research Network
Phase 3 Recruiting
NCT07018869 2025-12-05
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
SWOG Cancer Research Network
Phase 3 Recruiting
NCT02598349 2025-09-09
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Proton Collaborative Group
Phase 2 Recruiting
NCT06441747 2025-07-29
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Australasian Gastro-Intestinal Trials Group
Phase 2 Recruiting
NCT06290505 2025-07-23
PALEO
Australasian Gastro-Intestinal Trials Group
Phase 2 Recruiting
NCT05663502 2025-07-17
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
AIDS Malignancy Consortium
Recruiting
NCT06149546 2025-07-08
FEED
Cancer Trials Ireland
Phase NA Recruiting
NCT05518110 2024-09-26
PaTcH
Cancer Trials Ireland
Phase 2 Recruiting
NCT04498767 2024-08-26
OligoRARE
European Organisation for Research and Treatment of Cancer - EORTC
Phase NA Recruiting
NCT06212700 2024-04-25
PRIORITY-CONNECT 2 Pilot Trial
Surgical Outcomes Research Centre (SOuRCe)
Phase NA Recruiting
NCT04282083 2024-01-25
Protocol ITANET - Registry
Italian Association Neuroendocrine Tumors
Recruiting
NCT05935189 2023-07-07
TIR-HCC
Nikomed Medical Center
Recruiting